AWARD NUMBER: W81XWH-16-1-0300

TITLE: Metformin Therapy for Fanconis Anemia

PRINCIPAL INVESTIGATOR: Markus Grompe

CONTRACTING ORGANIZATION: Oregon Health & Science University
Portland OR 97239

REPORT DATE: August 2017

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
This award pertains to the treatment of the inherited bone marrow failure syndrome Fanconi’s Anemia. Specifically, the commonly used diabetes drug metformin will be tested by itself and in combination with the current standard of care, anabolic steroids.
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Introduction</td>
<td>4</td>
</tr>
<tr>
<td>2. Keywords</td>
<td>4</td>
</tr>
<tr>
<td>3. Accomplishments</td>
<td>4</td>
</tr>
<tr>
<td>4. Impact</td>
<td>5</td>
</tr>
<tr>
<td>5. Changes/Problems</td>
<td>5</td>
</tr>
<tr>
<td>6. Products</td>
<td>5</td>
</tr>
<tr>
<td>7. Participants &amp; Other Collaborating Organizations</td>
<td>6</td>
</tr>
<tr>
<td>8. Special Reporting Requirements</td>
<td>7</td>
</tr>
<tr>
<td>9. Appendices</td>
<td>7</td>
</tr>
</tbody>
</table>
1. Introduction
This award pertains to the treatment of the inherited bone marrow failure syndrome Fanconi’s Anemia. Specifically, the commonly used diabetes drug metformin will be tested by itself and in combination with the current standard of care, anabolic steroids.

2. Keywords
Fanconi Anemia, bone marrow failure, treatment, drug, small molecule, DNA damage, metformin

3. Accomplishments
We started work on this project less than a year ago and already have made good progress.

Major Goals:
Specific Aim 1: To evaluate metformin for the treatment of FA
Metformin is a biguanide drug widely used for the treatment of type 2 diabetes. In humans, it is known to have cancer chemoprevention properties. We found that MET enhances hematopoiesis specifically in Fancl2-/- mice, but how it does so is unclear. Here, we will determine whether MET acts via AMPK activation or as an aldehyde scavenger. We will ascertain whether it can prevent inflammation-induced anemia and whether it is beneficial when BMF has already started.

Specific Aim 2: To evaluate the combination of anabolic androgens with metformin for the treatment of FA.
Many FA patients respond to androgens by significant improvement of their blood counts. We now understand how androgens work and predict that there is no overlap with the mechanism of action of MET. Androgen therapy does not cure FA and we will therefore determine whether the combination of oxymetholone with metformin can synergistically improve hematopoiesis in FA.

Goals achieved:
Specific progress has been made on both Aims.

For Aim 1, we have generated a cohort of Fancl2 mutant mice to be aged until they display bone marrow failure. We plan to determine whether metformin can reverse already established anemia. Anemia developments take 12-18 months from birth and hence the metformin treatment will start at that time, during year 2 of the grant. We have also started a cohort of Fancl2/Aldh2 double mutant mice to address the question of whether metformin can directly scavenge aldehydes. In addition, we have generated some human Fanconia cell lines deficient in aldehyde metabolism to perform in vitro experiments in parallel.

Aim 2 has a timeline of over one year and generating the mice required to populate the project took considerable time, but has now been accomplished. We have populated four cohorts of FA mutant mice: 1) Mice receiving both oxymetholone and metformin; 2) mice receiving metformin alone; 3) mice receiving oxymetholone alone and 4) controls, receiving placebo (no drug). The experiments are ongoing. No overt side effects of the combination therapy have been seen.

Training opportunities:
Nothing to report.
Results dissemination:
Nothing to report.

Plans for the next reporting period:
We are pretty much on track of the timeline described in our application. A lot of experimental animals need to be generated by breeding and then aged from 6-18 months. Breeding efficiencies are only ¼ (recessive disease) and populating our study cohorts simply takes time. Hence, most of the experimental readouts will come in year 2 of the grant. We will complete Aim 2 and do a comprehensive analysis of the hematopoietic effects of combination therapy. The long term treatment will continue for another 9 months before analysis takes place. For completion of Aim 1, we need to generate a cohort of FA mice with already established bone marrow failure. These mice have been generated and now simply have to be aged. Despite our finding that metformin can in fact detoxify aldehydes, we will nonetheless complete our experiments aimed as assessing the role of AMPK activation.

4. Impact

Principal discipline:
Metformin has never been considered for the treatment of bone marrow failure before. Our preclinical data in mice are sufficiently compelling that a clinical trial of children with Fanconi Anemia with metformin is being implemented at Boston Childrens Hospital. The planned start date is January 2018.

Other disciplines:
Although hundreds of papers have been written about metformin and although many cancer prevention clinical trials are ongoing, metformin has never before been reported to block DNA damage and enhance genome integrity. The aldehyde scavenging effects of metformin have also not been previously reported. We believe that our findings provide a potential mechanism for the cancer prevention effects of metformin. This is a novel paradigm in the field.

Technology transfer:
Nothing to report.

Society:
Nothing to report.

5. Changes

Nothing to report.
We are happy to report that our experimental plans are coming off without a hitch and are on time.

6. Products

Spanish Fanconi Anemia Society Meeting, Madrid, Spain, June 2017: “Small Molecule Therapy of Fanconi Anemia”. Author: M. Grompe
7. **Participants and other collaborating organizations.**

**Individuals on the project**

<table>
<thead>
<tr>
<th>Name</th>
<th>Project Role</th>
<th>Researcher ID</th>
<th>Person month worked</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Markus Grompe, M.D.</td>
<td>Principal investigator</td>
<td>0000-0002-6616-4345</td>
<td>1</td>
<td>Overall experimental design. Oversight of project personnel; communication with funding agencies; manuscript writing.</td>
</tr>
<tr>
<td>Qingshuo Zhang, Ph.D.</td>
<td>Senior Research Associate</td>
<td></td>
<td>9</td>
<td>Dr. Zhang is the project leader in the lab; He designs most experiments (in collaboration with Dr. Grompe), performs experimentation himself, collects data and oversees the research assistants working on the project.</td>
</tr>
<tr>
<td>Leslie Wakefield</td>
<td>Research Assistant</td>
<td></td>
<td>3</td>
<td>Ms. Wakefield is in charge of our mouse animal colony (breeding, genotyping etc.) and assists Dr. Zhang with hands on experimentation.</td>
</tr>
<tr>
<td>Name</td>
<td>Sean Nygaard</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>-------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Project Role</td>
<td>Laboratory Manager</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Researcher ID</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Person month</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>worked</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contribution</td>
<td>Mr. Nygaard is in charge of overall lab organization, including order supplies, equipment maintenance, compliance (animal care).</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Funding support</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Changes:
Nothing to report

Other organizations:
Nothing to report.

8. Special Reporting Requirements

Nothing to report.

9. Appendices

Nothing to report